399 related articles for article (PubMed ID: 19336756)
1. Quality of life after allogeneic hematopoietic cell transplantation.
Pidala J; Anasetti C; Jim H
Blood; 2009 Jul; 114(1):7-19. PubMed ID: 19336756
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns.
Wong FL; Francisco L; Togawa K; Bosworth A; Gonzales M; Hanby C; Sabado M; Grant M; Forman SJ; Bhatia S
Blood; 2010 Mar; 115(12):2508-19. PubMed ID: 20089962
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.
El-Jawahri AR; Vandusen HB; Traeger LN; Fishbein JN; Keenan T; Gallagher ER; Greer JA; Pirl WF; Jackson VA; Spitzer TR; Chen YB; Temel JS
Cancer; 2016 Mar; 122(5):806-12. PubMed ID: 26650840
[TBL] [Abstract][Full Text] [Related]
6. Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation.
Hoodin F; LaLonde L; Errickson J; Votruba K; Kentor R; Gatza E; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Feb; 25(2):343-353. PubMed ID: 30244099
[TBL] [Abstract][Full Text] [Related]
7. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study.
Sun CL; Kersey JH; Francisco L; Armenian SH; Baker KS; Weisdorf DJ; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1073-80. PubMed ID: 23583827
[TBL] [Abstract][Full Text] [Related]
8. Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.
Umeda K
Int J Hematol; 2022 Jul; 116(1):41-47. PubMed ID: 35568772
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
10. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation.
Pallua S; Giesinger J; Oberguggenberger A; Kemmler G; Nachbaur D; Clausen J; Kopp M; Sperner-Unterweger B; Holzner B
Bone Marrow Transplant; 2010 Oct; 45(10):1534-9. PubMed ID: 20228854
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
13. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.
Hoffmeister PA; Storer BE; Macris PC; Carpenter PA; Baker KS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1081-6. PubMed ID: 23623893
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
15. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation.
Deschler B; Binek K; Ihorst G; Marks R; Wäsch R; Bertz H; Finke J
Biol Blood Marrow Transplant; 2010 Jul; 16(7):967-75. PubMed ID: 20144720
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease.
Kurosawa S; Oshima K; Yamaguchi T; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Kohno A; Miyamura K; Umemoto Y; Teshima T; Taniguchi S; Yamashita T; Inamoto Y; Kanda Y; Okamoto S; Atsuta Y
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1749-1758. PubMed ID: 28669922
[TBL] [Abstract][Full Text] [Related]
18. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
[TBL] [Abstract][Full Text] [Related]
19. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
